
Cancer Research UK and Dewpoint Therapeutics partner to advance potential
DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable driversCancer Research UK’s Centre for Drug Development has…
Read report ↗









